NCT03032666View on ClinicalTrials.gov

Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial

PHASE4CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

August 6, 2018

Study Completion Date

August 6, 2018

Conditions

ThalassemiaHepatitis C

Interventions

DRUG

sofosbuvir/velpatasvir

treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.

Trial Locations (1)

Unknown

American University of Beirut Medical Center, Beirut

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Ala'a Sharara

OTHER